Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.65 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.55 |
| ▸ | ITGAL | P20701 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21828671 | 0.97 | CYP3A4 (0.68) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL28806214 | 0.93 | CYP3A4 (0.59) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL27906686 | 0.91 | SLC15A2 (0.58) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL1230293 | 0.90 | CYP3A4 (0.65) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL29391246 | 0.89 | SLC15A2 (0.56) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL21828631 | 0.88 | CYP3A4 (0.63) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL31066556 | 0.88 | CYP3A4 (0.63) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL21748180 | 0.88 | CYP3A4 (0.59) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL29868096 | 0.88 | CYP3A4 (0.59) | CYP3A4SLC7A5SLC15A2ITGB2ICAM1 | |
| SCHEMBL29971719 | 0.88 | REN (0.60) | CYP3A4SLC7A5ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 853 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132176-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| CN-122012647-A | Method for hydrolyzing and saccharifying lignocellulose biomass | 贵州理工学院 | 2026-05-12 | — | — | CN | claimed |
| EP-3458477-B1 | ANTI-FACTOR IX PADUA ANTIBODIES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-09 | — | — | EP | claimed |
| WO-2024192296-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | TEH TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-19 | — | — | WO | claimed |
| US-11999798-B2 | Anti-factor IX padua antibodies | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-04 | — | — | US | claimed |
| US-20240151710-A1 | METHODS FOR DETECTING IMMUNE RESPONSE | MONASH UNIVERSITY (AU) | 2024-05-09 | — | — | US | claimed |
| EP-4270006-A2 | GENERAL DETECTION AND ISOLATION OF SPECIFIC CELLS BY BINDING OF LABELED MOLECULES | Immudex ApS (DK) | 2023-11-01 | — | — | EP | claimed |
| EP-4247968-A1 | USE OF DEXTRAMER IN SINGLE CELL ANALYSIS | Becton, Dickinson and Company (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230287369-A1 | A NEW, NON-SPECIFIC THERMOLABILE NUCLEASE ACTIVE AT LOW TEMPERATURE, IN WIDE PH RANGE AND HIGH CONCENTRATION IN SALTS | BLIRT S.A. (PL) | 2023-09-14 | — | — | US | claimed |
| CN-116615556-A | Use of DEXTRAMER in single cell assays | 贝克顿迪金森公司 | 2023-08-18 | — | — | CN | claimed |
| EP-3155426-B1 | GENERAL DETECTION AND ISOLATION OF SPECIFIC CELLS BY BINDING OF LABELED MOLECULES | IMMUDEX APS (DK) | 2023-07-19 | — | — | EP | claimed |
| EP-4045909-A1 | METHODS FOR DETECTING IMMUNE RESPONSE | Monash University (AU) | 2022-08-24 | — | — | EP | claimed |
| US-20220252594-A1 | GAMMA-DELTA T CELL LIGANDS FOR CANCER IMMUNOTHERAPY | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022129443-A1 | LATERAL FLOW TESTS | Coronex Limited (GB) | 2022-06-23 | — | — | WO | claimed |
| WO-2022109339-A1 | USE OF DEXTRAMER IN SINGLE CELL ANALYSIS | BECTON, DICKINSON AND COMPANY (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220064226-A1 | Panel comprising Borrelia MHC multimers | IMMUDEX APS (DK) | 2022-03-03 | — | — | US | claimed |
| US-12636417-B2 | Device for inline monitoring of free nucleosomes in blood | BELGIAN VOLITION SRL (BE) | 2026-05-26 | — | — | US | disclosed |
| WO-2026104826-A1 | METHOD OF GENERATING REGULATORY T CELLS | BIT BIO LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-20220033850-A1 | DESIGN OF BACTERIOPHAGE-BASED ARTIFICIAL VIRUSES FOR HUMAN GENOME REMODELING | THE CATHOLIC UNIVERSITY OF AMERICA | 2022-02-03 | — | — | US | disclosed |
| US-11236174-B2 | Therapeutic molecules | CRESCENDO BIOLOGICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132176-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | SUMO2, UBA2, SUMO3 | CYP3A4 3754/4885SLC7A5 2979/4885SLC15A2 1000/4885 |
| US-12636417-B2 | Device for inline monitoring of free nucleosomes in blood | H1-10, H1-2, H1-5 | CYP3A4 4589/4885SLC7A5 3962/4885SLC15A2 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.